U.S. market Open. Closes in 37 minutes

RVNC | Revance Therapeutics, Inc. Stock Overview

(Stock Exchange: NASDAQ)
Day's Range 3.56 - 4.00
52 Week Range 2.3000 - 24.87
Beta 0.48
Implied Volatility 320.28%
IV Rank 79.06%
Day's Volume 1,646,220
Average Volume 2,018,131
Shares Outstanding 104,448,000
Market Cap 377,579,520
Sector Healthcare
Industry Biotechnology
IPO Date 2014-02-06
Valuation
Profitability
Growth
Health
P/E Ratio -0.96
Forward P/E Ratio N/A
EPS -3.77
1YR Price Target N/A
Dividend Yield N/A
Dividend Per Share N/A
Dividend ExDate N/A
Dividend PayDate N/A
Employees 597
Country USA
Website RVNC
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials for the treatment of glabellar (frown) lines and cervical dystonia; is in phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis. It is also developing DaxibotulinumtoxinA in preclinical trial for the treatment of migraine, as well as a topical program for various indications; and OnabotulinumtoxinA, a biosimilar to BOTOX. The company has a collaboration and license agreement with Viatris Inc. to develop, manufacture, and commercialize onabotulinumtoxinA. The company was formerly known as Essentia Biosystems, Inc. and changed its name to Revance Therapeutics, Inc. in April 2005. Revance Therapeutics, Inc. was incorporated in 1999 and is headquartered in Nashville, Tennessee.
RVNC's peers: DMAC, AKRO, NUVL, IMCR, VTYX, ACLX, ETNB, PLRX, APLS, TERN, DAWN, BPMC, CERE, MDGL, STOK, ISEE, AMLX, KRTX
*Chart delayed
Analyzing fundamentals for RVNC we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is frighteningly weak. For more detailed analysis please see RVNC Fundamentals page.

Watching at RVNC technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, but short-term trend is bullish. More technicals details can be found on RVNC Technicals page.
An error has occurred. This application may no longer respond until reloaded. Reload 🗙